       Document 0443
 DOCN  M9620443
 TI    [The impact of the prevention of cerebral toxoplasmosis]
 DT    9602
 AU    Katlama C; Departement des Maladies Infectieuses, Hopital;
       Pitie-Salpetriere, Paris.
 SO    J Neuroradiol. 1995 Sep;22(3):193-5. Unique Identifier : AIDSLINE
       MED/96043315
 AB    In France, where 70% of adults are latently infected by toxoplasma, from
       20% to 40% of patients with AIDS developed toxoplasmic encephalitis
       until recently. The prophylactic use of drugs which are active against
       pneumocystis and toxoplasma has proven to be efficient. These drugs are
       trimethoprim-sulfamethoxazole or dapsone-pyrimethamine. With the extent
       of these primary prophylaxis, there is a decrease of risk of toxoplasma
       encephalitis; thus the rate of toxoplasma encephalitis among
       opportunistic infections has fallen off from 19% of the patients in 1988
       to 6% in 1994, in the department of infectious diseases of the
       Pitie-Salpetriere hospital. However, toxoplasmic abscesses occurring
       despite the prophylaxis are frequently slow growing lesions which can
       become huge with a moderate mass effect, mimicking the pattern of
       primary cerebral lymphoma. The rule of antitoxoplasmic trial treatment
       must be strictly followed, even under prophylaxis.
 DE    Adult  Anti-Infective Agents/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
       Antiprotozoal Agents/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/*PREVENTION & CONTROL  Brain
       Abscess/DIAGNOSIS/PARASITOLOGY  Brain Neoplasms/DIAGNOSIS
       Chemoprevention  Dapsone/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
       Diagnosis, Differential  Drug Combinations  Encephalitis/PREVENTION &
       CONTROL/PARASITOLOGY  English Abstract  France  Human  Lymphoma,
       AIDS-Related/DIAGNOSIS  Pyrimethamine/ADMINISTRATION &
       DOSAGE/THERAPEUTIC USE  Toxoplasmosis, Cerebral/*PREVENTION & CONTROL
       Trimethoprim-Sulfamethoxazole Combination/THERAPEUTIC USE  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

